MAPT and Alzheimer disease: 0N3R tau (Fig. 2a) with a cysteine-to-serine mutation (C322S) was the construct that most clearly discriminated AD from control brain, and did not show any self-aggregation in the absence of brain homogenate during a 200 h assay runtime (Additional file 1: Table S1).